Pratiwi, Chandrasasi Berlian
Unknown Affiliation

Published : 2 Documents Claim Missing Document
Claim Missing Document
Check
Articles

Found 2 Documents
Search

Curcumin in Turmeric (Curcuma longa L.) for Treatment of Oral Lichen Planus: A Narrative Review Purwaningrum, Vegananda Wahyu; Elizabeth, Laurencia Dwiamanda; Pratiwi, Chandrasasi Berlian; Nugraha, Ilyas Yakob Nurul; Setiawan, Kresna Erlangga; Maulina, Syafriaz Zulfa; Rahmah, Shafwa Aisha; Shallomitha, Aginta Gracia; Firjani, Putri Nabila; Supandji, Rafaelle Raditya; Salsabila, Alisya Rachel; Islamy, Azzahra Hasnur; Livesey, Gisele Nefertari Love; Masitoh, Hindun Fitria; Fadila, Okta Mulia Nur; Putri, Destiana Hardianti; Cinantya, Aulia Dian; Syahdiar, Aura Zalfa Ghassani; Wati, Sisca Meida; Rahayu, Retno Pudji; Budhy, Theresia Indah; Banerjee, Abhishek
Indonesian Journal of Dental Medicine Vol. 7 No. 1 (2024): Indonesian Journal of Dental Medicine
Publisher : Faculty of Dental Medicine Universitas Airlangga

Show Abstract | Download Original | Original Source | Check in Google Scholar | DOI: 10.20473/ijdm.v7i1.2024.40-43

Abstract

Background: Turmeric (Curcuma longa L.) has long been used as a traditional medicine. The primary active component of turmeric is curcumin. It has potential anti-inflammatory effects and high antioxidant activity. Curcumin contained in turmeric has been reported as an effective treatment for Oral lichen planus (OLP). OLP is a chronic autoimmune, inflammatory disease of the oral mucosa associated with systemic disease. This disease involves the skin and mucous membranes (mucocutaneous) of stratified squamous epithelium. Purpose: This narrative review conducted on Google Scholar, PubMed, Research Gate, and ScienceDirect databases aims to study the effectiveness of curcumin contained in Turmeric (C. longa L.)   in OLP treatment. Review(s): OLP is a condition of the oral mucosa that is a chronic autoimmune mucocutaneous disease. As many as 0.5% to 2.2% of cases of OLP occur in the adult population. Systemic and topical corticosteroid drugs are usually used to treat OLP. However, the use of these drugs has many side effects, so it needs searching for a new active substance to treat OLP. Curcumin is a hydrophobic polyphenol extracted from the rhizome of the herb Curcuma longa (turmeric), which has a low molecular weight. The repeated use of steroids can cause side effects that cause atrophy of the mucosa and candidiasis. One natural product that is superior to corticosteroids is curcumin. This is due to curcumin's anti-inflammatory, antioxidant, and chemopreventive properties in several diseases. Conclusion: This review suggests that OLP treatment using curcumin in Turmeric (C. longa L.)   is effective because curcumin exhibits antioxidant, anti-inflammatory, antimicrobial, and anticarcinogenic activities, as well as immunomodulatory properties.
Effect of chitosan–hydroxyapatite scaffolds seeded with cryopreserved hADMSCs on bone sialoprotein secretion Kamadjaja, Michael Josef Kridanto; Kuntjoro, Mefina; Pratiwi, Chandrasasi Berlian; Hartanli, Audrey Luisa
Majalah Kedokteran Gigi Indonesia Vol 11, No 3 (2025): December
Publisher : Faculty of Dentistry, Universitas Gadjah Mada

Show Abstract | Download Original | Original Source | Check in Google Scholar | DOI: 10.22146/majkedgiind.110209

Abstract

Tooth extraction can lead to alveolar bone resorption, requiring regenerative approaches using biomaterial scaffolds combined with stem cells. Chitosan–hydroxyapatite (CS–HA), a well-established scaffold that mimics the composition of human bone, combined with stem cells represents a promising strategy to promote bone formation. This study aimed to evaluate the effect of chitosan–hydroxyapatite (CS-HA) scaffolds seeded with cryopreserved human adipose-derived mesenchymal stem cells (hADMSCs) on bone sialoprotein (BSP) secretion. The hADMSCs used in this study were commercially obtained cryopreserved cells (ATCC® PCS-500-011™) and were characterized by flow cytometry. Scaffolds were fabricated using a freeze-drying method by combining chitosan and hydroxyapatite in a 1 : 1 ratio, followed by freezing at −80 °C. A post-test-only control group design was employed, consisting of 36 samples divided into three groups: positive control (CS-HA + hADMSCs + a-MEM), negative control (hADMSCs + osteogenic medium), and treatment (CS-HA + hADMSCs + osteogenic medium), and BSP levels were subsequently quantified on days 7, 14, 21, and 28 using ELISA. One-way ANOVA demonstrated a significant difference among groups (p = 0.000), with the highest BSP secretion observed in treatment group on day 14 (BSP levels 44.29 ± 2.58), followed by treatment group on day 28 (BSP levels 46.19 ± 7.64).  The significantly elevated BSP secretion in the treatment group on day 14 demonstrates osteoinductive characteristics of the CS-HA scaffold, supporting its potential application in bone tissue engineering and regeneration.